Equillium, Inc. (EQ): Operating Cash Flow
-$22.75M
Year ended 2025-12-31
-$19.97M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$22.75M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$19.03M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$21.78M | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$8.73M | n/m | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | -$32.08M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$24.62M | n/m | 2022-03-23, From 2020-01-01 |
| 2019-12-31 | -$22.95M | n/m | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | -$7.53M | n/a | 2020-03-26, From 2018-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Equillium, Inc. (EQ) | 2025-12-31 | -$22.75M | n/m |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | -$16.01M | n/m |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | -$23.50M | n/m |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | -$7.00M | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | -$9.90M | n/m |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $148.3K | n/m |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | -$27.75M | n/m |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | -$33.12M | n/m |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | -$5.33M | n/m |
Compare EQ, NVCT, TVRD, VBIO side by side · Screen every company in Pharmaceutical Preparations ↗